A Study of Chidamide With AZA in MRD Positive AML After Transplant

• Status: Recruiting
• Trial end date: 2026-12-01
• Target enrollment: 0
• Participant gender: All

Summary

acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong Provincial People's Hospital
• Collaborator: Shenzhen Chipscreen Biosciences Co.Ltd
• Treatments: Azacitidine

Criteria

Inclusion Criteria:

1. Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT);

2. ≥18 years old;

3. ECOG≤3;

4. lifespan≥3 months;

5. Take contraceptive measures;

6. Sign informed consent.

Exclusion Criteria:

1. Allergic to the study drug;

2. A gastrointestinal condition that prevents oral medication;

3. active infection;

4. Dysfunction of vital organs;

5. other malignancies;

6. HIV infection;

7. HBV or HCV;

8. The QT interval is prolonged;

9. Pregnant or lactating women;

10. Is participating in other clinical studies;

11. The researchers did not consider it appropriate to participate in this study.